OS Therapies Incorporated

OSTX

$1.93

+5.77%

2026-09-04 10:35:24 EDT+$0.11

Healthcare

Biotechnology

AMEX

Active Trading

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid ...

Price Action of OSTX

$1.93

+5.77%+$0.11

High—

Low—

52W High-17.9%

Rel. vol—

Interval

Range63m

Volume—SMA5SMA10

—

OS Therapies Incorporated (OSTX) is a clinical-stage biopharmaceutical company headquartered in Grasonville, Maryland, and listed on the NYSE Arca. Founded in 2018, the company is dedicated to addressing the unmet medical needs of patients with osteosarcoma and other solid tumors, an area where no new treatments have emerged in over ...OS Therapies Incorporated (OSTX) is a clinical-stage biopharmaceutical company headquartered in Grasonville, Maryland, and listed on the NYSE Arca. Founded in 2018, the company is dedicated to addressing the unmet medical needs of patients with osteosarcoma and other solid tumors, an area where no new treatments have emerged in over 30 years. The company’s pipeline features two proprietary technologies: OST-HER2, an off-the-shelf immunotherapy aimed at treating osteosarcoma, and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate platform that employs pH-sensitive silicone linkers for targeted drug delivery. These technologies are designed to activate the immune system and improve therapeutic outcomes. As a small company with only 4 full-time employees, OS Therapies operates efficiently, leveraging the experience of its leadership team, including CEO Paul Romness, who has over 25 years in the biopharmaceutical industry with experience at Johnson & Johnson and Amgen. Financially, the company is in its early stage, reporting no revenue, negative earnings, and negative cash flows from operations, which is typical for clinical-stage biotech firms. The company’s market capitalization is approximately $72.9 million, with a stock price around $1.60. Despite the challenging financial metrics, including negative book value and negative return on assets, the company is actively investing in research and development to advance its pipeline. The company's focus on pediatric cancer and solid tumors, combined with its innovative technology, positions it as a potential player in the oncology space, though significant risks remain given the early stage of development and limited resources.ExpandCollapse

Founded

2018

Employees

CEO

Paul A. Romness

Full Name

OS Therapies Incorporated

Sector

Healthcare

Industry

Biotechnology

ROE

683.03%

Market Cap

$0.09B

Current Ratio

0.18

WACC

5.48%

ROIC

365.21%

Contact Information

https://ostherapies.com

410-297-7793

115 Pullman Crossing Road, Grasonville, MD 21638

Key Metrics of OSTX

Snapshot

Latest / TTM · 6 periods

Market Cap

$89.46M

ROCE

350.1%

EV / EBITDA

-2.13x

-232.8% YoY

FCF Yield

-22.4%

+34744.7% YoY

Cash Conversion Cycle

-18374.5d

Current Ratio

0.18

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of OSTX

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-1.67x

n/a

Debt / Equity

0.00

n/a

Current Ratio

0.18

Dividend Yield

0.0%

Understanding

TTM —

Current ratio below 1.0

Interest coverage is weak

Calendar of OSTX

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.14 · Revenue $1.00M · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.16 · Revenue $1.67M · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.76 · Revenue $2.00M · 2 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.05 · Revenue $8.74M · 1 analysts

Recent history

Aug 14, 2026
Q2 FY2026 · Results reported
EPS $-0.20 · Revenue $0.00
View filing
May 18, 2026
Q1 FY2026 · Results reported
EPS $-0.27 · Revenue $0.00
View filing
Mar 31, 2026
FY2025 · Annual results
EPS $-0.98 · Revenue $0.00
View filing
Nov 14, 2025
Q3 FY2025 · Results reported
EPS $-0.21 · Revenue $0.00
View filing
Aug 18, 2025
Q2 FY2025 · Results reported
EPS $-0.18 · Revenue $0.00
View filing
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $-0.18 · Revenue $0.00

Financial Statements of OSTX

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-28.8M	-223.7%	+17.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-14.2B	-195423.2%	-21.2%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.0%	—	+100.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	0.03x	-97.6%	+225.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$6.8M	+23.5%	+35.6%

Actual vs Estimate

A Dec 31Q Sep 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.98 vs -0.69	-42.0%	-0.20 vs -0.14	-37.9%
Revenue Surprise	$0 vs $36.7M	-100.0%	$0 vs $1.0M	-100.0%

Insider Transactions of OSTX

Acquisitions (A)

Since Oct 21, 2025

Disposals (D)

Since Oct 21, 2025

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 1, 2026	EAGLE CRAIG	director:	—	—	0	—
Jan 22, 2026	McKean-Dieser Avril Suzette	director	Stock options (right to buy)	A	50,000	$1.34
Jan 22, 2026	Search Theodore F.	director	Stock options (right to buy)	A	50,000	$1.34
Jan 22, 2026	Ciccio John	director	Stock options (right to buy)	A	50,000	$1.34
Jan 22, 2026	Acevedo Christopher P.	officer: Chief Financial Officer	Stock options (right to buy)	A	100,000	$1.34

Leadership Team of OSTX

6 executives

Name	Title	Compensation	Gender	Year Born	Status
Paul A. Romness	Founder, Chairman, President & Chief Executive Officer	USD 722,168	Male	1966	Active
Robert G. Petit	Chief Medical Officer & Chief Scientific Officer	USD 420,000	—	1960	Active
Christopher Acevedo	Chief Financial Officer	USD 36,000	Male	1963	Active
Jack Doll	Chief of Staff	—	Male	—	Active
Gerald E. Commissiong	Chief Business Officer	—	Male	1982	Active
Craig Eagle	Chief Medical Advisor, Member of Strategic Advisory Board & Director	—	—	1967	Active

Recent News of OSTX

Newsfile Corp2 days agoNeutral

OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance

Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business development advisors will attend BioJapan Interim 3-year overall survival data, U.S. FDA Type C Statistical Methods meeting and U.K. MHRA Statistical Methods Scientific Advice Meeting expected in September 2026 RMAT and Rolling Review decisions expected to follow U.S. FDA meeting Final 3-year overall survival data, U.S. FDA Pre-BLA Meeting, BLA submission, MHRA CMAA submission, and EMA CMAA submission expected in Q4 2026 Confirmatory Phase 3 Clinical Trial Application to follow MHRA meeting for Q4 2026 trial commencement OS Animal Health to attend Moody Capital Disruptive Growth & Life Sciences Conference New York and Rockville, Maryland--(Newsfile Corp. - September 2, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that its management team, its business development advisors and the management team of its wholly-owned subsidiary OS Animal Health will participate in upcoming conferences, and provided a program update for OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program"): Jefferies Global Healthcare Conference: London - November 16-19, 2026 H.C.

Newsfile Corp8/17/2026Neutral

OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates

Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closing FDA Type C Statistical Methods Meeting mid-September 2026 meeting to review 2.5-year Overall Survival data and confirmatory Phase 3 trial design to gain alignment on statistical analysis plan for BLA submission under the Accelerated Approval Program Interim 3-year Overall Survival data expected in early September 2026 ahead of MHRA Statistical Methods Scientific Advice Meeting for Conditional MAA submission acceptance criteria Final 3-year Overall Survival data to be included in FDA BLA Accelerated Approval Program submission ahead of Type B Pre-BLA Meeting previously granted in Q2/26 U.K. waives Pediatric Investigation Plan (PIP) requirement New York and Rockville, Maryland--(Newsfile Corp. - August 17, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today reported financial results for the second fiscal quarter ended June 30, 2026, and provided business and regulatory updates. The Company is seeking to obtain a Biologics License Application (BLA) under the Accelerated Approval Program of the U.S. Food & Drug Administration (FDA), and equivalent Conditional Marketing Accelerated Authorisations (CMAAs) from the Medicines and Healthcare products Regulatory Agency (MHRA) and European Medicines Agency (EMA), for OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program").

Newsfile Corp8/13/2026Neutral

OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma

Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling Review expected following this meeting Sustained overall survival benefit observed between 2-year and 2.5-year timepoints U.K. MHRA Statistical Methods Scientific Advice Meeting granted in parallel New York, New York and Rockville, Maryland--(Newsfile Corp. - August 13, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company's requested Type C Statistical Methods meeting to review the 2.5 year overall survival data from the Phase 2b trial of OST-HER2 in the prevention of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Trial"). The Company expects the FDA Type C Statistical Methods Meeting to occur in mid-September 2026 with members from division within the Center for Biologics Evaluation and Research (CBER), in parallel with the pending Biomarker Data Review Meeting being scheduled with members of the Center for Drug Evaluation and Research's (CDER) Biomarker Qualification Program (BQP).

Newsfile Corp7/8/2026Neutral

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program

CDER meeting expected to take place in the summer of 2026 in parallel with CBER's Type B Statistical Methods Meeting New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has accepted a new Meeting Request from the U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) to review the Company's pharmacodynamic response biomarker data (the "OST-HER2 Biomarker Data") – patent pending. CDER's Biomarkers, EndpointS, and other Tools (BEST) resources is part of its Biomarker Qualification Program (BQP).

Newsfile Corp7/6/2026Neutral

OS Therapies Third Quarter 2026 Corporate Outlook

Upcoming Type B Statistical Methods Meeting expected to set stage for FDA to align with EMA and MHRA on use of Fall 2026 3-year overall survival data combined with biomarkers to support early market access New York, New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The outlook focuses on upcoming clinical and regulatory milestones for the Company's lead program OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Metastatic Osteosarcoma Program"), advancements with the Company's animal health-focused subsidiary OS Animal Health, Inc. (OSAH) and the Company's financial position as key regulatory and corporate milestones come into focus.

Historical Employee Count of OSTX

Current

Change

+0.00%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	4	10-K	Mar 31, 2026	View
Dec 31, 2024	4	10-K	Mar 31, 2025	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

OS Therapies Incorporated